Bioventus Inc. revised earnings guidance for the full-year 2024. Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects Net sales of $535 million to $550million, an increase of $15 million from previous guidance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.38 USD | -3.77% | +18.15% | +21.06% |
May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.06% | 407M | |
+73.24% | 12.39B | |
-19.09% | 7.89B | |
+13.24% | 5.43B | |
+38.48% | 4.96B | |
-17.30% | 4.72B | |
-19.78% | 4.02B | |
-29.53% | 2.66B | |
+47.29% | 2.37B | |
-2.10% | 1.96B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024